vs
普立万（AVNT）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
普立万的季度营收约是Royalty Pharma plc的1.2倍（$760.6M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 2.2%，领先32.2%），Royalty Pharma plc同比增速更快（4.8% vs 1.9%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -4.2%）
普立万公司是一家全球性材料解决方案供应商，总部位于美国俄亥俄州埃文湖，全球员工约9000人。主营产品涵盖色母粒、先进复合材料、功能添加剂以及工程材料，为多行业客户提供定制化的材料相关技术支持与解决方案。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
AVNT vs RPRX — 直观对比
营收规模更大
AVNT
是对方的1.2倍
$622.0M
营收增速更快
RPRX
高出2.9%
1.9%
净利率更高
RPRX
高出32.2%
2.2%
两年增速更快
RPRX
近两年复合增速
-4.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $760.6M | $622.0M |
| 净利润 | $16.9M | $214.2M |
| 毛利率 | 30.2% | — |
| 营业利润率 | 5.2% | 62.4% |
| 净利率 | 2.2% | 34.4% |
| 营收同比 | 1.9% | 4.8% |
| 净利润同比 | -65.0% | 2.9% |
| 每股收益（稀释后） | $0.18 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVNTRPRX
| Q4 25 | $760.6M | $622.0M | ||
| Q3 25 | $806.5M | $609.3M | ||
| Q2 25 | $866.5M | $578.7M | ||
| Q1 25 | $826.6M | $568.2M | ||
| Q4 24 | $746.5M | $593.6M | ||
| Q3 24 | $815.2M | $564.7M | ||
| Q2 24 | $849.7M | $537.3M | ||
| Q1 24 | $829.0M | $568.0M |
净利润AVNTRPRX
| Q4 25 | $16.9M | $214.2M | ||
| Q3 25 | $32.6M | $288.2M | ||
| Q2 25 | $52.6M | $30.2M | ||
| Q1 25 | $-20.2M | $238.3M | ||
| Q4 24 | $48.3M | $208.2M | ||
| Q3 24 | $38.2M | $544.0M | ||
| Q2 24 | $33.6M | $102.0M | ||
| Q1 24 | $49.4M | $4.8M |
毛利率AVNTRPRX
| Q4 25 | 30.2% | — | ||
| Q3 25 | 30.4% | — | ||
| Q2 25 | 32.1% | — | ||
| Q1 25 | 31.8% | — | ||
| Q4 24 | 34.8% | — | ||
| Q3 24 | 32.1% | — | ||
| Q2 24 | 30.3% | — | ||
| Q1 24 | 33.6% | — |
营业利润率AVNTRPRX
| Q4 25 | 5.2% | 62.4% | ||
| Q3 25 | 8.3% | 70.1% | ||
| Q2 25 | 11.1% | 36.3% | ||
| Q1 25 | 0.1% | 94.0% | ||
| Q4 24 | 11.5% | 60.9% | ||
| Q3 24 | 9.5% | — | ||
| Q2 24 | 8.5% | 50.2% | ||
| Q1 24 | 11.3% | -13.0% |
净利率AVNTRPRX
| Q4 25 | 2.2% | 34.4% | ||
| Q3 25 | 4.0% | 47.3% | ||
| Q2 25 | 6.1% | 5.2% | ||
| Q1 25 | -2.4% | 41.9% | ||
| Q4 24 | 6.5% | 35.1% | ||
| Q3 24 | 4.7% | 96.3% | ||
| Q2 24 | 4.0% | 19.0% | ||
| Q1 24 | 6.0% | 0.8% |
每股收益（稀释后）AVNTRPRX
| Q4 25 | $0.18 | $0.49 | ||
| Q3 25 | $0.36 | $0.67 | ||
| Q2 25 | $0.57 | $0.07 | ||
| Q1 25 | $-0.22 | $0.55 | ||
| Q4 24 | $0.53 | $0.46 | ||
| Q3 24 | $0.41 | $1.21 | ||
| Q2 24 | $0.36 | $0.23 | ||
| Q1 24 | $0.54 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $618.7M |
| 总债务越低越好 | $1.9B | $9.0B |
| 股东权益账面价值 | $2.4B | $9.7B |
| 总资产 | $6.0B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.81× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资AVNTRPRX
| Q4 25 | — | $618.7M | ||
| Q3 25 | — | $938.9M | ||
| Q2 25 | — | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $929.0M | ||
| Q3 24 | — | $950.1M | ||
| Q2 24 | — | $1.8B | ||
| Q1 24 | — | $843.0M |
总债务AVNTRPRX
| Q4 25 | $1.9B | $9.0B | ||
| Q3 25 | $2.0B | $8.9B | ||
| Q2 25 | $2.0B | $8.0B | ||
| Q1 25 | $2.1B | $7.6B | ||
| Q4 24 | $2.1B | $7.6B | ||
| Q3 24 | $2.1B | $7.6B | ||
| Q2 24 | $2.1B | $7.6B | ||
| Q1 24 | $2.1B | $6.1B |
股东权益AVNTRPRX
| Q4 25 | $2.4B | $9.7B | ||
| Q3 25 | $2.4B | $9.6B | ||
| Q2 25 | $2.4B | $9.5B | ||
| Q1 25 | $2.3B | $9.8B | ||
| Q4 24 | $2.3B | $10.3B | ||
| Q3 24 | $2.4B | $10.3B | ||
| Q2 24 | $2.3B | $9.8B | ||
| Q1 24 | $2.3B | $9.9B |
总资产AVNTRPRX
| Q4 25 | $6.0B | $19.6B | ||
| Q3 25 | $6.1B | $19.3B | ||
| Q2 25 | $6.1B | $18.3B | ||
| Q1 25 | $5.8B | $17.6B | ||
| Q4 24 | $5.8B | $18.2B | ||
| Q3 24 | $6.0B | $18.0B | ||
| Q2 24 | $5.9B | $17.7B | ||
| Q1 24 | $5.9B | $16.1B |
负债/权益比AVNTRPRX
| Q4 25 | 0.81× | 0.92× | ||
| Q3 25 | 0.83× | 0.93× | ||
| Q2 25 | 0.86× | 0.84× | ||
| Q1 25 | 0.90× | 0.78× | ||
| Q4 24 | 0.89× | 0.74× | ||
| Q3 24 | 0.88× | 0.74× | ||
| Q2 24 | 0.90× | 0.78× | ||
| Q1 24 | 0.90× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $167.8M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $125.4M | — |
| 自由现金流率自由现金流/营收 | 16.5% | — |
| 资本支出强度资本支出/营收 | 5.6% | — |
| 现金转化率经营现金流/净利润 | 9.93× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $195.0M | — |
8季度趋势，按日历期对齐
经营现金流AVNTRPRX
| Q4 25 | $167.8M | $827.1M | ||
| Q3 25 | $72.1M | $702.6M | ||
| Q2 25 | $112.8M | $364.0M | ||
| Q1 25 | $-51.1M | $596.1M | ||
| Q4 24 | $122.6M | $742.5M | ||
| Q3 24 | $71.1M | $703.6M | ||
| Q2 24 | $105.9M | $658.2M | ||
| Q1 24 | $-42.8M | $664.6M |
自由现金流AVNTRPRX
| Q4 25 | $125.4M | — | ||
| Q3 25 | $47.4M | — | ||
| Q2 25 | $85.8M | — | ||
| Q1 25 | $-63.6M | — | ||
| Q4 24 | $81.5M | — | ||
| Q3 24 | $46.1M | — | ||
| Q2 24 | $74.5M | — | ||
| Q1 24 | $-67.2M | — |
自由现金流率AVNTRPRX
| Q4 25 | 16.5% | — | ||
| Q3 25 | 5.9% | — | ||
| Q2 25 | 9.9% | — | ||
| Q1 25 | -7.7% | — | ||
| Q4 24 | 10.9% | — | ||
| Q3 24 | 5.7% | — | ||
| Q2 24 | 8.8% | — | ||
| Q1 24 | -8.1% | — |
资本支出强度AVNTRPRX
| Q4 25 | 5.6% | — | ||
| Q3 25 | 3.1% | — | ||
| Q2 25 | 3.1% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 5.5% | — | ||
| Q3 24 | 3.1% | — | ||
| Q2 24 | 3.7% | — | ||
| Q1 24 | 2.9% | — |
现金转化率AVNTRPRX
| Q4 25 | 9.93× | 3.86× | ||
| Q3 25 | 2.21× | 2.44× | ||
| Q2 25 | 2.14× | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | 2.54× | 3.57× | ||
| Q3 24 | 1.86× | 1.29× | ||
| Q2 24 | 3.15× | 6.45× | ||
| Q1 24 | -0.87× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVNT
| Color Additives And Inks | $466.0M | 61% |
| Specialty Engineered Materials | $295.5M | 39% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
